ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lun…

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

ImmunityBio: Why I Am Upgrading To A Buy For 2026

ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
Morning Overview on MSN

Scientists find a way to turbocharge cancer-fighting immunity

Cancer immunotherapy has already transformed treatment for some patients, yet too often the body’s defenders stall out before ...
Seeking Alpha

ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access ...
Medscape

Pregnancy and Breastfeeding May Reprogram Breast Immunity

Pregnancy and breastfeeding leave behind long-lived CD8+ T lymphocytes that provide lasting immune protection in breast tissue, according to new research, a discovery that could reshape understanding ...